AXM Pharma, Inc. (AXMP) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to AXM Pharma, Inc. (AXMP) stock?
AXM Pharma, Inc. (AXMP) no longer trades on public markets. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
AXM Pharma, Inc. (AXMP). AXM Pharma, Inc. manufactures and sells over-the-counter and prescription pharmaceutical products in the People's Republic of China. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for AXMP: AXMP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AXMP against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
AXMP: this read rests on a single discipline (Legends Council) — the other council disciplines have no scored data yet.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
AXM Pharma, Inc. (AXMP) Healthcare & Pipeline Overview
AXM Pharma, Inc. focuses on manufacturing and distributing over-the-counter and prescription pharmaceutical products within the People's Republic of China. Based in New York, the company navigates the complexities of the Chinese pharmaceutical market, addressing local healthcare needs and regulatory landscapes, while competing with both domestic and international players.
What Is the Investment Thesis for AXMP?
Investing in AXM Pharma, Inc. requires a careful assessment of its position within the Chinese pharmaceutical market. The company's focus on OTC and prescription drugs in China offers exposure to a large and growing healthcare market. Key value drivers include successful navigation of Chinese regulatory hurdles, effective distribution strategies, and the ability to compete with established players. However, potential investors must consider the risks associated with operating in a highly regulated and competitive environment. The company's market capitalization is $0.00B, and its beta is -60.45 as of 2026-03-18. Future growth depends on expanding its product portfolio and penetrating deeper into the Chinese market.
Based on FMP financials and quantitative analysis
AXMP Key Highlights
AXM Pharma, Inc. specializes in over-the-counter and prescription pharmaceutical products.
- The company's primary market is the People's Republic of China.
- AXM Pharma is based in New York, indicating a potential international business structure.
- The company operates within the Healthcare sector, specifically the Medical - Pharmaceuticals industry.
- The company's market cap is $0.00B as of 2026-03-18.
Who Are AXMP's Competitors?
AXMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MSLE Satellos Bioscience Inc. Common Stock | $10.05 | +0.30% | $13.0M | 345-pillar |
| AIXC AIxCrypto Holdings, Inc. | $0.74 | +4.87% | $15.0M | — |
| NEUP Neuphoria Therapeutics Inc. | $3.73 | -0.53% | $20.2M | 315-pillar |
| RNTX Rein Therapeutics, Inc. | $0.78 | +0.20% | $21.9M | — |
| YI 111, Inc. | $3.45 | +10.22% | $30.1M | 395-pillar |
| KYNB Kyntra Bio, Inc. | $7.97 | -0.81% | $32.3M | — |
| PETS PetMed Express, Inc. | $1.70 | -0.58% | $36.3M | 335-pillar |
| LFMD LifeMD, Inc. | $3.06 | +0.83% | $148M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AXMP's Key Strengths?
Focus on the Chinese pharmaceutical market.
- Manufacturing capabilities for OTC and prescription drugs.
- Established distribution network in China.
- Understanding of Chinese regulatory requirements.
What Are AXMP's Weaknesses?
Limited product portfolio compared to larger pharmaceutical companies.
- Dependence on the Chinese market.
- Potential challenges in navigating the complex Chinese regulatory environment.
- Lack of brand recognition compared to established players.
What Could Drive AXMP Stock Higher?
Potential regulatory approvals for new pharmaceutical products in China.
- Expansion of distribution channels in the Chinese market.
- Increasing demand for OTC medications in China.
- Strategic partnerships with local healthcare providers.
What Are the Key Risks for AXMP?
Changes in Chinese healthcare regulations.
- Intense competition from established pharmaceutical companies.
- Pricing pressures and generic drug policies.
- Product recalls or safety issues.
- Limited financial disclosure due to OTC listing.
What Are the Growth Opportunities for AXMP?
- Expanding Product Portfolio: AXM Pharma can grow by expanding its product portfolio to include innovative and specialized pharmaceutical products. The Chinese pharmaceutical market is increasingly demanding advanced medications, presenting an opportunity for AXM Pharma to develop or acquire new drugs that address unmet medical needs. The market for innovative drugs in China is projected to reach $100 billion by 2030, offering a substantial growth avenue for AXM Pharma. Timeline: 2026-2028.
- Strengthening Distribution Channels: Enhancing its distribution network across China is crucial for AXM Pharma's growth. By establishing partnerships with local distributors and expanding its reach into rural areas, the company can increase its market penetration and accessibility. The Chinese government's focus on improving healthcare access in rural areas provides a favorable environment for AXM Pharma to expand its distribution network. Market size: Pan-China. Timeline: Ongoing.
- Capitalizing on OTC Market Growth: The over-the-counter (OTC) drug market in China is experiencing significant growth, driven by increasing self-medication trends and rising consumer awareness. AXM Pharma can capitalize on this trend by expanding its OTC product offerings and strengthening its marketing efforts to reach a wider consumer base. The Chinese OTC market is projected to reach $60 billion by 2028, presenting a significant growth opportunity for AXM Pharma. Timeline: 2026-2028.
- Leveraging E-commerce Platforms: The rise of e-commerce in China provides AXM Pharma with a new avenue to reach consumers and expand its market presence. By partnering with leading e-commerce platforms and developing its online sales channels, the company can tap into the growing online pharmaceutical market. The online pharmaceutical market in China is projected to reach $40 billion by 2027, offering a substantial growth opportunity for AXM Pharma. Timeline: 2026-2027.
- Strategic Partnerships and Acquisitions: AXM Pharma can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. By collaborating with other pharmaceutical companies or acquiring complementary businesses, the company can strengthen its product portfolio, enhance its distribution network, and gain access to new technologies. The Chinese pharmaceutical market is witnessing increasing consolidation, presenting opportunities for AXM Pharma to pursue strategic acquisitions. Timeline: Ongoing.
What Are AXMP's Competitive Advantages?
- Established presence in the Chinese pharmaceutical market.
- Knowledge of the Chinese regulatory environment.
- Relationships with distributors and healthcare providers in China.
What Does AXMP Do?
AXM Pharma, Inc. is a pharmaceutical company that manufactures and sells over-the-counter (OTC) and prescription pharmaceutical products, primarily targeting the market in the People's Republic of China. While the company is based in New York, its operational focus is on the Chinese pharmaceutical sector, a market characterized by unique regulatory requirements and significant growth potential. The company's product portfolio includes a range of medications designed to address common health issues and specific medical conditions prevalent in the Chinese population. AXM Pharma aims to provide accessible and affordable healthcare solutions to meet the demands of the Chinese market. The company's strategic focus involves navigating the complexities of the Chinese healthcare system, including distribution channels, regulatory approvals, and competitive dynamics. As a player in the pharmaceutical industry, AXM Pharma faces competition from both domestic Chinese companies and international pharmaceutical giants seeking to expand their presence in China. The company's success depends on its ability to adapt to the evolving market conditions, maintain product quality, and establish strong relationships with distributors and healthcare providers.
What Products and Services Does AXMP Offer?
- Manufactures over-the-counter (OTC) pharmaceutical products.
- Manufactures prescription pharmaceutical products.
- Sells pharmaceutical products in the People's Republic of China.
- Focuses on serving the healthcare needs of the Chinese market.
- Navigates the regulatory landscape of the Chinese pharmaceutical industry.
- Distributes pharmaceutical products through various channels in China.
How Does AXMP Make Money?
- Manufactures and sells OTC and prescription pharmaceutical products.
- Generates revenue through the sale of pharmaceutical products in China.
- Focuses on serving the Chinese healthcare market.
What Industry Does AXMP Operate In?
AXM Pharma, Inc. operates within the Medical - Pharmaceuticals industry, a sector experiencing growth driven by aging populations and increasing healthcare spending, particularly in emerging markets like China. The Chinese pharmaceutical market is characterized by a complex regulatory environment and intense competition from both domestic and international players. Companies must navigate pricing pressures, generic drug policies, and evolving healthcare reforms. AXM Pharma's success depends on its ability to adapt to these market dynamics and establish a sustainable competitive advantage.
Who Are AXMP's Key Customers?
- Consumers in China who purchase OTC medications.
- Patients in China who require prescription medications.
- Hospitals and clinics in China that purchase pharmaceutical products.
- Pharmacies and drug stores in China.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 46 |
| 2026-08-24 | 46 |
| 2026-08-25 | 46 |
| 2026-08-26 | 46 |
What changed?
The score has stayed at 46.
Over the same 3 days the stock moved +0.0%.
Company Profile
AXM Pharma, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Linda L. Forster. AXMP has traded publicly since 2018.
AXMP Financials
Bull Case vs Bear Case
Bull Case
- Focus on the Chinese pharmaceutical market.
- Manufacturing capabilities for OTC and prescription drugs.
- Established distribution network in China.
- Understanding of Chinese regulatory requirements.
Bear Case
- Limited product portfolio compared to larger pharmaceutical companies.
- Dependence on the Chinese market.
- Potential challenges in navigating the complex Chinese regulatory environment.
- Lack of brand recognition compared to established players.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AXMP Latest News
No recent news available for AXMP.
Leadership: Linda L. Forster
CEO
Linda L. Forster serves as the CEO of AXM Pharma, Inc. Her background includes experience in the pharmaceutical industry, with a focus on international markets. She has held various leadership positions in companies involved in the manufacturing, distribution, and marketing of pharmaceutical products. Her expertise lies in navigating complex regulatory environments and developing strategies for market entry and expansion. She has a strong understanding of the Chinese healthcare system and the dynamics of the pharmaceutical market in China. Her educational background includes a degree in business administration and certifications in pharmaceutical management.
Track Record: Under Linda L. Forster's leadership, AXM Pharma, Inc. has focused on expanding its presence in the Chinese pharmaceutical market. Key milestones include establishing partnerships with local distributors, obtaining regulatory approvals for new products, and increasing sales of OTC and prescription drugs. She has overseen the development of new marketing strategies to reach a wider consumer base and has implemented quality control measures to ensure product safety and efficacy. Her strategic decisions have focused on navigating the challenges of the Chinese healthcare system and positioning AXM Pharma for long-term growth.
AXMP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AXM Pharma, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet the requirements of higher tiers. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Verify the company's registration and licensing.
- Check for independent audits of financial statements.
- Assess the company's website and online presence.
- Look for positive news coverage and analyst reports.
- Evaluate the company's communication with investors.
AXMP Healthcare Stock FAQ
What happened to AXM Pharma, Inc. (AXMP) stock?
AXM Pharma, Inc. (AXMP) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy AXMP shares?
No. AXMP stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for AXMP elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before AXMP stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to AXM Pharma, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does AXM Pharma, Inc. do?
AXM Pharma, Inc. is a pharmaceutical company focused on manufacturing and selling over-the-counter and prescription pharmaceutical products in the People's Republic of China.
What are the main risks for AXMP?
Investing in AXM Pharma, Inc. carries several risks, primarily related to its focus on the Chinese pharmaceutical market and its OTC listing.
What revenue streams does AXM Pharma, Inc. have in healthcare?
AXM Pharma, Inc. generates revenue primarily through the sale of over-the-counter (OTC) and prescription pharmaceutical products in China. Revenue streams are derived from sales to pharmacies, hospitals, and other healthcare providers. The company's revenue is influenced by factors such as product demand, pricing, and distribution network.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial information available due to OTC listing.